CD14 antagonist antibodies for treating neurodegenerative diseases
AssigneeImplicit Bioscience Limited
InventorGarry Llewellyn Redlich
Life of this patent
Estimating the term…
Abstract
This invention relates generally to agents and methods for treating the development or progression of a neurodegenerative disease. In particular, the present invention relates to CD14 antagonists for use in treating the development or progression of a neurodegenerative disease, including Motor Neurone Disease (MND) and Dementia disease or associated symptoms. The present invention further provides compositions including such agents.
Claims6
A method for treating the development or progression of amyotrophic lateral sclerosis (ALS) or a symptom thereof in a subject, the method comprising administering systemically an effective amount of a CD14 antagonist antibody to the subject, wherein the CD14 antagonist antibody comprises a VL domain and a VH domain, wherein:
- the VL domain comprises a L-CDR1, a L-CDR2 and a L-CDR3 within the sequence set forth in SEQ ID NO:25;
- and
- the VH domain comprises a H-CDR1, a H-CDR2 and a H-CDR3 within the sequence set forth in SEQ ID NO:26.
Dependencies are inferred from the claim text.